Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Cavosonstat in Healthy Subjects
NCT02013388Phase 1Completed
- Sponsor
- Nivalis Therapeutics
- Start
- Feb 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cavosonstat in cystic fibrosis (CF) (8 arms), sponsored by Nivalis Therapeutics. Primary endpoints: Safety and Tolerability of N91115 at 21 Days, Pharmacokinetics: Day 1 AUClast and 3 more. Started Feb 2014; status: completed.
02
Drugs
cavosonstat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02013388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013388.